Rezultati pretrage - Wilbraham, Darren

  • Prikaz rezultata 1 – 11 od 11
Detaljiziraj rezultate
  1. 1
    A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

    A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD or... od Stott, Colin, White, Linda, Wright, Stephen, Wilbraham, Darren, Guy, Geoffrey

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  2. 2
    Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol

    Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol od Tsai, Max, Case, Michael, Ardayfio, Paul, Hochstetler, Helen, Wilbraham, Darren

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  3. 3
    Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

    Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects od Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Kielbasa, William

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  4. 4
    Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects

    Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects od Harada, Tomohiko, Wilbraham, Darren, de La Borderie, Guillemette, Inoue, Shinsuke, Bush, Jim, Camm, A. John

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  5. 5
    Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease

    Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease od Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Pugh, Melissa, Ardayfio, Paul, Kielbasa, William

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  6. 6
    Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men

    Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men od Scott, Graham, Ahmad, Irfan, Howard, Katy, MacLean, David, Oliva, Cristina, Warrington, Steve, Wilbraham, Darren, Worthington, Paul

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  7. 7
    Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects

    Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects od Juif, Pierre-Eric, Baldoni, Daniela, Reyes, Maribel, Wilbraham, Darren, Febbraro, Salvatore, Vaclavkova, Andrea, Hoch, Matthias, Dingemanse, Jasper

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  8. 8
    Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study

    Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study od Wilbraham, Darren, Berg, Paul H., Tsai, Max, Liffick, Emily, Loo, Li Shen, Doty, Erin Gautier, Sellers, Edward

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  9. 9
    Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls

    Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls od Pearlman, Eric M., Wilbraham, Darren, Dennehy, Ellen B., Berg, Paul H., Tsai, Max, Doty, Erin G., Kay, Gary G.

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  10. 10
    Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

    Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine od Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  11. 11
    Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men

    Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men od Sun, Hong, Kennedy, William P., Wilbraham, Darren, Lewis, Nicole, Calder, Nicole, Li, Xiaodong, Ma, Junshui, Yee, Ka Lai, Ermlich, Susan, Mangin, Eric, Lines, Christopher, Rosen, Laura, Chodakewitz, Jeffrey, Murphy, Gail M.

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:

Alati za pretragu: